Table 3.

All-cause TEAEs occurring in ≥ 10% of patients in the safety population in either study portion

TEAE, n (%)	Dose escalation (n = 25)		Dose expansion (n = 18)
	All grades	Grade ≥ 3	All grades	Grade ≥ 3
At least one TEAE	25 (100)	12 (48)	18 (100)	9 (50)
Nausea	12 (48)	0	8 (44)	1 (6)
Diarrhea	10 (40)	0	6 (33)	2 (11)
Fatigue	10 (40)	3 (12)	11 (61)	2 (11)
Anemiaa	9 (36)	1 (4)	6 (33)	0
Rash	8 (32)	0	2 (11)	0
Decreased appetite	7 (28)	0	5 (28)	0
Hyperglycemia	7 (28)	0	3 (17)	0
Vomiting	6 (24)	0	6 (33)	1 (6)
Hypokalemia	6 (24)	1 (4)	5 (28)	1 (6)
Hypoalbuminemia	6 (24)	0	2 (11)	0
Hypomagnesemia	6 (24)	0	1 (6)	0
Back pain	6 (24)	0	0	0
Hypocalcemia	5 (20)	0	1 (6)	0
Increased alkaline phosphatase	5 (20)	0	0	0
Abdominal pain	4 (16)	1 (4)	3 (17)	0
Dehydration	4 (16)	1 (4)	3 (17)	1 (6)
Dyspepsia	4 (16)	0	1 (6)	0
Increased AST	4 (16)	0	0	0
Decreased weight	3 (12)	0	6 (33)	0
Dyspnea	3 (12)	1 (4)	4 (22)	2 (11)
Dysuria	3 (12)	0	2 (11)	0
Hyponatremia	3 (12)	1 (4)	1 (6)	0
Constipation	3 (12)	0	1 (6)	0
Stomatitis	3 (12)	0	1 (6)	0
Disease progression	3 (12)	3 (12)	1 (6)	1 (6)
Edema peripheral	3 (12)	1 (4)	1 (6)	1 (6)
Dizziness	3 (12)	0	1 (6)	1 (6)
Pain in extremities	3 (12)	1 (4)	0	0
Hypotension	3 (12)	1 (4)	0	0
Headache	2 (8)	0	2 (11)	0
Muscle spasms	2 (8)	0	2 (11)	0
Musculoskeletal pain	1 (4)	0	3 (17)	0
Prolonged activated partial thromboplastin time	1 (4)	1 (4)	2 (11)	1 (6)
Asthenia	1 (4)	0	2 (11)	0
Cough	1 (4)	0	2 (11)	0
Decreased ejection fraction	1 (4)	0	2 (11)	0
Flank pain	1 (4)	0	2 (11)	1 (6)
Exertional dyspnea	0	0	5 (28)	1 (6)
Urinary tract infection	0	0	4 (22)	0
Lymphopenia	0	0	2 (11)	0
Pyrexia	0	0	2 (11)	0
Thrombocytopenia	0	0	2 (11)	0
Decreased potassium	0	0	2 (11)	0

AST aspartate aminotransferase, TEAE treatment-emergent adverse event

^aIncludes grouped terms: anemia, hemoglobin decreased